Comparative Hepatoprotective Evaluation of Calotropis gigantea Root and Portulaca oleracea Foliated-Stem Extracts, Alone and in Combination, Against Carbon Tetrachloride-Induced Hepatotoxicity in Wistar Rats

References

[1] Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171.

[2] Bishayee A, Sarkar A, Chatterjee M. Hepatoprotective activity of carrot (Daucus carota L.) against carbon tetrachloride intoxication in mouse liver. J Ethnopharmacol. 1995;47(2):69–74.

[3] Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003;33(2):105–136.

[4] Recknagel RO, Glende EA, Dolak JA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther. 1989;43(1):139–154.

[5] Manibusan MK, Odin M, Eastmond DA. Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health C. 2007;25(3):185–209.

[6] Slater TF. Free-radical mechanisms in tissue injury. Biochem J. 1984;222(1):1–15.

[7] Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351–358.

[8] Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–77.

[9] Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968;25:192–205.

[10] Halliwell B, Gutteridge JM. Free Radicals in Biology and Medicine. 5th ed. Oxford: Oxford University Press; 2015.

[11] Girish C, Koner BC, Jayanthi S, Rao KR, Rajesh B, Pradhan SC. Hepatoprotective activity of six polyherbal formulations in CCl4-induced liver toxicity in mice. Indian J Exp Biol. 2009;47(4):257–263.

[12] Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124(5):491–504.

[13] Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035–2063.

[14] Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–1432.

[15] Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants (Basel). 2015;4(1):204–247.

[16] Ramachandra Setty S, Quereshi AA, Viswanath Swamy AH, et al. Hepatoprotective activity of Calotropis procera flowers against paracetamol-induced hepatic injury in rats. Fitoterapia. 2007;78(7–8):451–454.

[17] Kumar G, Karthik L, Rao KV. A review on pharmacological and phytochemical properties of Calotropis procera (Ait.) R. Br. (Asclepiadaceae). Asian J Pharm Clin Res. 2011;4(2):1–7.

[18] Basu A, Chaudhuri AK. Preliminary studies on the antiinflammatory and analgesic activities of Calotropis procera root extract. J Ethnopharmacol. 1991;31(3):319–324.

[19] Sharma AK, Kharb R, Kaur R. Pharmacognostical aspects of Calotropis gigantea (L.) R. Br. Int J Pharm Pharm Sci. 2011;3(2):15–17.

[20] Rathod NR, Raghuveer I, Chitme HR, Chandra R. Free radical scavenging activity of Calotropis gigantea root bark. Pharmacologyonline. 2008;1:378–387.

[21] Kumar S, Dewan S, Sangraula H, Kumar VL. Antidiarrhoeal activity of the latex of Calotropis procera. J Ethnopharmacol. 2001;76(1):115–118.

[22] Dewan S, Sangraula H, Kumar VL. Preliminary studies on the analgesic activity of latex of Calotropis procera. J Ethnopharmacol. 2000;73(1–2):307–311.

[23] Nenaah G. Antibacterial and antifungal activities of (E,E)-α-farnesene isolated from the aerial parts of Calotropis procera. J Taibah Univ Sci. 2013;7(4):197–204.

[24] Rastogi S, Kumar R, Chaudhary GN, Mishra V. Phytochemical screening and GC-MS profiling of Calotropis gigantea extracts. J Pharmacogn Phytochem. 2016;5(3):200–205.

[25] Xiang L, Xing D, Wang W, Wang R, Ding Y, Du L. Alkaloids from Portulaca oleracea L. Phytochemistry. 2005;66(21):2595–2601.

[26] Yang Z, Liu C, Xiang L, Zheng Y. Phenolic alkaloids as a new class of antioxidants in Portulaca oleracea. Phytother Res. 2009;23(7):1032–1035.

[27] Uddin MK, Juraimi AS, Hossain MS, Un A, Ali M, Rahman MM. Purslane weed (Portulaca oleracea): a prospective plant source of nutrition, omega-3 fatty acid, and antioxidant attributes. ScientificWorldJournal. 2014;2014:951019.

[28] Zhu H, Wang Y, Liu Y, Xia Y, Tang T. Analysis of flavonoids in Portulaca oleracea L. by UV-vis spectrophotometry with comparative study on different extraction technologies. Food Anal Methods. 2010;3(2):90–97.

[29] Chan K, Islam MW, Kamil M, et al. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. sativa (Haw.) Celak. J Ethnopharmacol. 2000;73(3):445–451.

[30] Gong F, Li F, Zhang L, Li J, Zhang Z, Wang G. Hypoglycemic effects of crude polysaccharide from Purslane (Portulaca oleracea L.) in normal and diabetic mice. Molecules. 2009;14(12):4844–4854.

[31] Rashed AN, Afifi FU, Disi AM. Simple evaluation of the wound healing activity of a crude extract of Portulaca oleracea L. (growing in Jordan) in Mus musculus JVI-1. J Ethnopharmacol. 2003;88(2–3):131–136.

[32] Erkan N. Antioxidant activity and phenolic compounds of fractions from Portulaca oleracea L. Food Chem. 2012;133(3):775–781.

[33] Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. London: Chapman and Hall; 1998.

[34] Evans WC. Trease and Evans' Pharmacognosy. 16th ed. Edinburgh: Saunders Elsevier; 2009.

[35] Sofowora A, Ogunbodede E, Onayade A. The role and place of medicinal plants in the strategies for disease prevention. Afr J Tradit Complement Altern Med. 2013;10(5):210–229.

[36] Organisation for Economic Co-operation and Development. Test No. 423: Acute Oral Toxicity - Acute Toxic Class Method. OECD Guidelines for the Testing of Chemicals, Section 4. Paris: OECD Publishing; 2002.

[37] Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). CPCSEA Guidelines for Laboratory Animal Facility. Indian J Pharmacol. 2003;35:257–274.

[38] Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008;245(3):194–205.

[39] Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367–379.

[40] Amacher DE. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol. 1998;27(2):119–130.

[41] Ahmed B, Alam T, Varshney M, Khan SA. Hepatoprotective activity of two plants belonging to the Apiaceae and the Euphorbiaceae family. J Ethnopharmacol. 2002;79(3):313–316.

@article{1724049,
      author = {Niketa, Prashant Kumar Singh},
      title = {Comparative Hepatoprotective Evaluation of Calotropis gigantea Root and Portulaca oleracea Foliated-Stem Extracts, Alone and in Combination, Against Carbon Tetrachloride-Induced Hepatotoxicity in Wistar Rats},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {4},
      pages = {2501-2510},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1724049.pdf},
      abstract = {Carbon tetrachloride (CCl4)-induced hepatotoxicity is a well-established experimental model for evaluating hepatoprotective agents, given its reproducible induction of oxidative hepatocellular injury via cytochrome P450-mediated bioactivation to the trichloromethyl free radical [3-6]. This study evaluated the comparative and combined hepatoprotective potential of methanolic extracts of Calotropis gigantea root and Portulaca oleracea foliated stem against CCl4-induced hepatotoxicity in Wistar rats. Extracts were obtained by cold maceration (6.30% w/w and 8.40% w/w yield respectively) and screened for phytoconstituents, both testing positive for flavonoids, alkaloids, glycosides, saponins and tannins. Acute oral toxicity testing (OECD 423) confirmed safety up to 2000 mg/kg, and doses of 100, 200 and 400 mg/kg were selected for the main study. Sixty male Wistar rats were divided into ten groups (n = 6): normal control, CCl4 toxic control, silymarin (50 mg/kg), three dose levels each of C. gigantea and P. oleracea, and a low-dose combination. CCl4 administration markedly elevated serum ALT, AST, ALP and bilirubin and hepatic malondialdehyde while depleting glutathione and body/liver-weight indices; both extracts dose-dependently attenuated these changes, with C. gigantea 400 mg/kg (74.6% hepatoprotection), P. oleracea 400 mg/kg (78.5%) and particularly the combination (85.4%, approaching silymarin's 87.7%) producing the most pronounced normalisation, corroborated by histopathological improvement from severe centrilobular necrosis to near-normal architecture. These findings support a synergistic, antioxidant-mediated hepatoprotective action for the combined extracts, comparable to standard silymarin therapy.},
      keywords = {Calotropis gigantea; Portulaca oleracea; hepatoprotective activity; carbon tetrachloride; oxidative stress; silymarin; polyherbal combination; Wistar rats},
      month = {October},
  }